Skip to main content
Premium Trial:

Request an Annual Quote

Diagnoplex Gets $8.3M in Series A Financing

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Diagnoplex today said that it has closed a Series A financing round, raising CHF 10 million ($8.3 million) in funding.
Diagnoplex said that it would use proceeds from the financing to further develop its Colox non-invasive test for early detection of colon cancer.
The firm’s tests are based on its single-channel quantitative multiplex reverse transcriptase-polymerase chain reaction (scqmRT-PCR) platform that can quantify up to 60 genes simultaneously. According to the firm, the technology pairs the high accuracy and reliability of PCR with the possibility to read out multi-gene signatures of different cancers. It noted that unlike microarray platforms, its platform is easily scalable and can be run in most standardized testing labs.
The round of financing was led by Novartis Venture Fund and NeoMed, with additional investment from Initiative Capital Romandie. Novartis Venture Fund previously was a seed investor in Diagnoplex.
In connection with the funding, Anja König, managing director of Novartis Venture Fund, and NeoMed Principal Thomas Goebel will join Diagnoplex’s board of directors.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.